Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Preclinical data support the clinical potential of Turnstone’s next-generation Selected TIL therapy to improve TIL efficacy against solid tumor malignancies

Presentations highlight novel method to select the most potent tumor-reactive T-cells (Selected TILs) with the potential to overcome the limitations of conventional TIL-based therapies

SAN DIEGO--(BUSINESS WIRE)--Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, today announced that two posters showing preclinical data from the Company’s novel tumor-infiltrating lymphocyte (TIL) therapy will be presented at the Society for Immunotherapy of Cancer (SITC) 37^th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022.

The posters, one of which is to be presented in collaboration with Moffitt Cancer Center, will showcase data demonstrating the successful expansion and enrichment of tumor-reactive TILs from colorectal cancer tumor samples, providing support for the application of TIDAL-01 as a therapy for solid tumors. TIDAL-01, Turnstone’s lead TIL therapy candidate, focuses on selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) to overcome the limitations of current TIL-based therapies.

“Over the years, we have witnessed remarkable durable responses in a limited number of solid tumor types following treatment with TILs,” said Stewart Abbot, Ph.D., Chief Scientific Officer, Turnstone Biologics. “Our preclinical datasets demonstrate greater promise for our Selected TILs compared to conventional TIL-based therapies to target a broader range of solid tumors. With our recently accepted INDs for TIDAL-01, we are eager to translate these promising results into the clinic, including through our strategic alliance with Moffitt.”

The full abstracts are available on the SITC website, and details of the poster presentations are as follows:

Presented jointly with Moffitt Cancer Center
Title: Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal cancer (CRC)
Session: Cellular Therapies
Session Date and Time: November 10, 2022, 9:00 a.m. – 9:00 p.m.
Location: Poster Hall C
Abstract Number: 387

Turnstone presentation
Title: Enrichment of neoantigen reactive TIL in a CRC patient sample by FACS: The TIDAL-01 process
Session: Cellular Therapies
Session Date and Time: November 11, 2022, 9:00 a.m. – 8:30 p.m.
Location: Poster Hall C
Abstract Number: 404

About Turnstone Biologics

Turnstone Biologics, a clinical stage biotechnology company, is developing new medicines to treat and cure solid tumors by pioneering a differentiated approach with a clinically validated technology, tumor infiltrating lymphocyte (TIL) therapy. Turnstone’s innovative TIL therapy, which is designed to extend the efficacy of TILs to multiple solid tumor indications by selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) for tumor eradication, represents the Company’s foundational therapeutic modality driving its cancer immunotherapy pipeline. The Company’s lead Selected TIL therapy candidate, TIDAL-01, is expected to initiate clinical trials in 2022. Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.

For more information, please visit www.turnstonebio.com, and follow us on LinkedIn.